Gujarat Magazine

Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharma

 Breaking News
  • No posts were found

Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharma

June 04
07:46 2024
Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharma
Non-Alcoholic Steatohepatitis Pipeline Insight 2024
Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics

As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Alcoholic Steatohepatitis (NASH) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-Alcoholic Steatohepatitis Market. 

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Non-Alcoholic Steatohepatitis Therapeutic Segment @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Non-Alcoholic Steatohepatitis (NASH) Therapeutics Assessment

There are approx. 130+ key companies developing therapies for Non-Alcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Non-Alcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market Include:

Akero Therapeutics, Albireo Pharma, Altimmune, Inc., Amgen, ARTham Therapeutics, Ascletis, AstraZeneca, Bird Rock Bio, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cirius Therapeutics, DURECT Corporation, Enanta Pharmaceuticals, Enzychem Lifesciences, Galecto Biotech, Gmax Biopharm, GSK plc., Guangdong Zhongsheng Pharmaceutical, Hepion Pharmaceuticals, Ildong Pharmaceutical, Ildong Pharmaceutical, InorbitTX, Ionis Pharmaceuticals, J2H Biotech, LG Chem Life sciences, Liminal BioSciences, Madrigal Pharmaceuticals, Melior Pharmaceuticals, Merck Sharp & Dohme LLC, NorthSea Therapeutics, Palobiofarma, Pharmaxis, Pliant Therapeutics, Rivus Pharmaceuticals, Sciwind Biosciences, SCOHIA PHARMA, TaiwanJ Pharmaceuticals, Thoth Science, Tiziana Life Sciences, TransThera Biosciences, Viking Therapeutics, and many others.

Non-Alcoholic Steatohepatitis Emerging and Marketed Drugs Covered in the Report Include:

  • Resmetirom: Madrigal Pharmaceuticals

  • MSDC-0602K: Cirius Therapeutics

  • ION224: Ionis Pharmaceuticals

  • HU 6: Rivus Pharmaceuticals

  • HTD 1801: HighTide Biopharma

  • EDP-305: Enanta Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Table of Contents

1. Report Introduction

2. Executive Summary

3. Non-Alcoholic Steatohepatitis Current Treatment Patterns

4. Non-Alcoholic Steatohepatitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Alcoholic Steatohepatitis Late Stage Products (Phase-III)

7. Non-Alcoholic Steatohepatitis Mid-Stage Products (Phase-II)

8. Non-Alcoholic Steatohepatitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Alcoholic Steatohepatitis Discontinued Products

13. Non-Alcoholic Steatohepatitis Product Profiles

14. Key Companies in the Non-Alcoholic Steatohepatitis Market

15. Key Products in the Non-Alcoholic Steatohepatitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Non-Alcoholic Steatohepatitis Unmet Needs

18. Non-Alcoholic Steatohepatitis Future Perspectives

19. Non-Alcoholic Steatohepatitis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories